Benzinga | Mar 17, 2021 06:49AM EDT

Cowen & Co. Downgrades GenMark Diagnostics to Market Perform, Raises Price Target to $24.05

Cowen & Co. analyst Doug Schenkel downgrades GenMark Diagnostics (NASDAQ:GNMK) from Outperform to Market Perform and raises the price target from $23 to $24.05.